Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tate Thigpen

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology|February 8, 2006
The role of maintenance therapy and novel taxanes in ovarian cancerThomas J Herzog, Robert L Coleman, Maurie Markman, et al.
Gynecologic Oncology|September 19, 2003
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, George Olt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyL R Bigler, J Tate Thigpen, J A Blessing, et al.
Gynecologic Oncology|April 22, 2004
Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, Koen DeGeest, et al.
Gynecologic Oncology|September 25, 2012
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyFrederick B Stehman, Mark F Brady, J Tate Thigpen, et al.
Cancer|August 26, 2010
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysisKathleen N Moore, Chunqiao Tian, D Scott McMeekin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group studyJ Tate Thigpen, Mark F Brady, Howard D Homesley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2007
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group StudyPeter G Rose, Shamshad Ali, Edwin Watkins, et al.
Gynecologic Oncology|June 19, 2007
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group studyD Scott McMeekin, Virginia L Filiaci, J Tate Thigpen, et al.
Gynecologic Oncology|December 8, 2006
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group studySusan C Modesitt, Chunqiao Tian, Richard Kryscio, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology|February 8, 2006
The role of maintenance therapy and novel taxanes in ovarian cancerThomas J Herzog, Robert L Coleman, Maurie Markman, et al.
Gynecologic Oncology|September 19, 2003
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, George Olt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyL R Bigler, J Tate Thigpen, J A Blessing, et al.
Gynecologic Oncology|April 22, 2004
Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, Koen DeGeest, et al.
Gynecologic Oncology|September 25, 2012
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyFrederick B Stehman, Mark F Brady, J Tate Thigpen, et al.
Cancer|August 26, 2010
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysisKathleen N Moore, Chunqiao Tian, D Scott McMeekin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group studyJ Tate Thigpen, Mark F Brady, Howard D Homesley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2007
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group StudyPeter G Rose, Shamshad Ali, Edwin Watkins, et al.
Gynecologic Oncology|June 19, 2007
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group studyD Scott McMeekin, Virginia L Filiaci, J Tate Thigpen, et al.
Gynecologic Oncology|December 8, 2006
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group studySusan C Modesitt, Chunqiao Tian, Richard Kryscio, et al.
Pageof 4